COA and batch documentation
Pyk2-PRR2 Peptide Research: Invadopodia Models and Metastasis Biology
A rebuilt article on the Bar-Ilan Pyk2-PRR2 peptide study, focused on invadopodia biology, cortactin interaction, and preclinical evidence limits.
The older title described a peptide as stopping cancer from spreading into the blood. That is too absolute. The source topic is better framed as Pyk2-PRR2 peptide research in invadopodia-mediated metastasis models.
Research context
The Bar-Ilan Oncogene paper describes a Pyk2-derived cell-permeable peptide designed to interfere with the interaction between Pyk2 and cortactin in invadopodia. The study reported effects on cortactin phosphorylation, actin polymerization, invadopodia maturation, and spontaneous lung metastasis in immune-competent mouse breast-cancer models. Earlier invadopodia papers help explain why cortactin, N-WASP, Arp2/3, cofilin, and matrix-degradation assays matter in this area.
For Adria, the correct article is about protein-protein interaction, SH3-domain binding, invadopodia biology, preclinical model design, and translation limits. It should not be presented as a cancer-prevention product, metastasis applied-use, or medical breakthrough for use.
Documentation context
When a research peptide is derived from a protein interaction domain, sequence identity and batch documentation are central. The record should include the exact peptide name, batch number, COA, storage conditions, and source map.
Adria research-use note
This article is a literature overview only. It is not cancer, metastasis, applied-use, practical-use, non-laboratory-use, or non-laboratory-use guidance.
Evidence checkpoints for this topic
Pyk2 is most useful in the archive when it is read through immune-marker literature, cytokine or cell-marker endpoints, antimicrobial membrane models, and cohort or assay limitations. A stronger article does not only name a peptide or pathway; it explains what kind of evidence the source actually provides and what remains outside the source.
In this article, sources such as Pyk2-derived peptide and invadopodia-mediated breast cancer metastasis models, Molecular mechanisms of invadopodium formation, Cortactin, invadopodia formation, and metastasis model literature should be read for their specific methods, endpoints, and limits. That makes the article more useful for a research archive because a reader can see whether a statement comes from a primary experiment, a review, a mechanistic assay, or a documentation-style discussion.
- Model: check whether the paper uses purified peptide, fragment variants, cell-marker panels, membrane assays, cohort data, or model-organism work.
- Endpoint: record cytokine panels, T-cell markers, membrane disruption, antibody titers, microbial model readouts, or inflammation-marker measurements.
- Comparator: verify the control condition, assay medium, sequence variant, timing, and whether the result is mechanistic or observational.
- Documentation: keep sequence identity, batch traceability, COA context, storage condition, and source link together.
- Limit: keep visible why immune-pathway language needs conservative framing and source-level wording.
What a careful reader can take from it
The practical value of this post is the structure it gives to the literature. Instead of treating every source as equal, the reader can separate the question being asked, the method used to ask it, and the claim that can reasonably follow. That is especially important in peptide topics, where online summaries often compress receptor data, model endpoints, supplier documentation, and broad interpretation into one sentence.
For Adria, the useful standard is simple: every strong sentence should be traceable to a source, every source should be described by its model and endpoint, and product-adjacent language should point back to analytical documentation rather than unsupported claims. This is why the article keeps PubMed, PMC, DOI, or documentation links visible instead of hiding the evidence trail.